Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus-loaded Punctal Plug for Dry Eye Disease
NCT05618730Phase 1Active, not recruiting
- Sponsor
- Eximore
- Start
- Sep 2022
- Primary completion
- Dec 2023
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tacrolimus in dry eye disease (DED) (2 arms), sponsored by Eximore. Primary endpoints: Adverse Events Frequency, Severity, and Duration at 6 weeks and Number of Participants with Treatment-Related Adverse Events at 6 weeks. Started Sep 2022; status: active, not recruiting.
02
Drugs
tacrolimus
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT05618730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05618730.